mhurhangee/patent-ind-claim-en huggingface dataset:
Apparatus for moving a heavy weight radiography device for industrial applications, comprising: - a substantially rectangular frame extending parallel to a plane (X-Z) parallel to a longitudinal lengthwise direction (X-X) of the apparatus and to a vertical heightwise direction (Z-Z) of the apparatus, having a greater dimension parallel to the vertical direction (Z-Z) and translatably movable in both senses of the longitudinal direction (X-X) via means for translational movement of the frame ; - a first carriage movable on the frame in both senses of the vertical direction (Z-Z); - a second carriage mounted on and displaceable relative to the first carriage in both senses of a transverse direction (Y-Y) orthogonal to the longitudinal (X-X) and vertical (Z-Z) directions and adapted to rotate about an axis parallel to the vertical direction (Z-Z); - a bottom support for the radiography device , mounted on the second carriage and adapted to swivel about an axis parallel to the longitudinal direction (X-X), relative to the second carriage ; - a beam extending in the longitudinal direction (X-X) and able to be fixed to a wall, said beam comprising means complementing the means for translational movement of the frame which may thereby move on the beam in both senses of the said longitudinal direction (X-X); wherein in an intermediate position in the vertical direction (Z-Z) the frame has counter-thrust struts , extending parallel to the transverse direction (Y-Y) for keeping, during use, the frame spaced and aligned with respect to a wall to which the beam is also fixed. - a substantially rectangular frame extending parallel to a plane (X-Z) parallel to a longitudinal lengthwise direction (X-X) of the apparatus and to a vertical heightwise direction (Z-Z) of the apparatus, having a greater dimension parallel to the vertical direction (Z-Z) and translatably movable in both senses of the longitudinal direction (X-X) via means for translational movement of the frame ; - a first carriage movable on the frame in both senses of the vertical direction (Z-Z); - a second carriage mounted on and displaceable relative to the first carriage in both senses of a transverse direction (Y-Y) orthogonal to the longitudinal (X-X) and vertical (Z-Z) directions and adapted to rotate about an axis parallel to the vertical direction (Z-Z); - a bottom support for the radiography device , mounted on the second carriage and adapted to swivel about an axis parallel to the longitudinal direction (X-X), relative to the second carriage ; - a beam extending in the longitudinal direction (X-X) and able to be fixed to a wall, said beam comprising means complementing the means for translational movement of the frame which may thereby move on the beam in both senses of the said longitudinal direction (X-X);
A method for temperature calibration and determination of a temperature in a scene, wherein the method comprises: - at each time point of a plurality of time points in a first period of time, collecting an ambient temperature representing a temperature at a first part of the scene to obtain collected ambient temperatures spanning over a range of ambient temperatures, and, by means of a thermal camera , collecting one or more thermal image sensor signal values corresponding to the collected ambient temperatures and relating to the first part of the scene, wherein the first part of the scene is a background part of the scene; - determining a calibration function based on the collected ambient temperatures and the one or more thermal image sensor signal values corresponding to each of the collected ambient temperatures, wherein the calibration function gives temperature as a function of thermal image sensor value; - in a second period of time and by means of the thermal camera , capturing a thermal image of the scene comprising thermal image sensor signal values relating to a second part of the scene; and - in the second period of time, determining a temperature at the second part of the scene based on the calibration function and based on one or more thermal image sensor signal values comprised in the captured thermal image of the scene and relating to the second part of the scene. - at each time point of a plurality of time points in a first period of time, collecting an ambient temperature representing a temperature at a first part of the scene to obtain collected ambient temperatures spanning over a range of ambient temperatures, and, by means of a thermal camera , collecting one or more thermal image sensor signal values corresponding to the collected ambient temperatures and relating to the first part of the scene, wherein the first part of the scene is a background part of the scene; - determining a calibration function based on the collected ambient temperatures and the one or more thermal image sensor signal values corresponding to each of the collected ambient temperatures, wherein the calibration function gives temperature as a function of thermal image sensor value; - in a second period of time and by means of the thermal camera , capturing a thermal image of the scene comprising thermal image sensor signal values relating to a second part of the scene; and - in the second period of time, determining a temperature at the second part of the scene based on the calibration function and based on one or more thermal image sensor signal values comprised in the captured thermal image of the scene and relating to the second part of the scene.
An apparatus for preparing food, comprising: - a food preparation chamber ; - an air movement device ; - a heating device ; and - air guiding means , wherein the food preparation chamber is provided by a container structure at least partly enclosing a receiving volume for receiving food to be prepared by a through-streaming of hot air; wherein the container structure comprises sidewalls and a bottom wall , wherein the bottom wall and/or one of the side walls is air-permeable providing an air entry opening for entering of hot air into the receiving volume, and wherein the container structure comprises an air discharge opening , wherein the heating device is configured to heat air of an air flow provided by the air movement device, wherein the air guiding means provide an air duct arrangement , and wherein a collecting device with a collection volume is provided below the food preparation chamber for collecting residual material; characterized in that : the air duct arrangement is provided from the discharge opening via the heating device and the air movement device to the air entry opening; an air guiding element is provided that directs a horizontal supply air-flow below the container structure in an upwards direction towards the air entry opening; and the collecting device is arranged besides the air guiding element on a side facing away from the horizontal supply air-flow. - a food preparation chamber ; - an air movement device ; - a heating device ; and - air guiding means , the air duct arrangement is provided from the discharge opening via the heating device and the air movement device to the air entry opening; an air guiding element is provided that directs a horizontal supply air-flow below the container structure in an upwards direction towards the air entry opening; and the collecting device is arranged besides the air guiding element on a side facing away from the horizontal supply air-flow.
A method of forming an implantable prosthesis, comprising the steps of: co-extruding a first material and a second material, such that, after extrusion, the second material defines at least one elongate structure surrounded by the matrix of the first material; expanding the first material; sintering the first material; removing the second material from of the first material to leave a void in the first material; and filling the voids left in the first material, after removal of the second material, with a drug. co-extruding a first material and a second material, such that, after extrusion, the second material defines at least one elongate structure surrounded by the matrix of the first material; expanding the first material; sintering the first material; removing the second material from of the first material to leave a void in the first material; and filling the voids left in the first material, after removal of the second material, with a drug.
A medical arm system comprising: an endoscope ; a multi-joint arm which has a plurality of links connected by joints and a distal end to which the endoscope is connected; and a control unit which is configured to set a virtual surface in a body cavity of a patient , and to control the multi-joint arm so as to constrain a predetermined point of the endoscope in the body cavity on the virtual surface, wherein the control unit limits a movement speed of the predetermined point to a predetermined speed or lower. an endoscope ; a multi-joint arm which has a plurality of links connected by joints and a distal end to which the endoscope is connected; and a control unit which is configured to set a virtual surface in a body cavity of a patient , and to control the multi-joint arm so as to constrain a predetermined point of the endoscope in the body cavity on the virtual surface, wherein the control unit limits a movement speed of the predetermined point to a predetermined speed or lower.
A latent heat exchange chamber having an arrangement and condensing on its outer face and evaporating on its inner face; characterized in that an outer face of the chamber is covered, at least in part, with microgrooves or other capillary structure, wherein the microgrooves or other capillary structure are configured to allow vapour to condense in a capillary regime forming condensing menisci with a concave liquid-vapour interface inside the microgrooves or other capillary structure; wherein an inner face of the chamber is covered, at least in part, with microgrooves or micro undulations, the microgrooves or micro undulations being configured to allow a liquid to be evaporated to flow through them forming evaporating menisci with a concave liquid-vapour interface inside the microgrooves or micro undulations such that the evaporation occurs from the upper end of the menisci where the evaporation is most efficient; the arrangement comprising a liquid supplying system configured to supply the liquid to be evaporated without obstructions, in a direct and controlled manner, on the inner face of the chamber without undesired liquid overflows in the microgrooves or micro undulations in such a way that dry areas are reduced or eliminated; and wherein one section of the chamber wall of the chamber has a zigzag, crenellated or corrugated shape in the direction of the microgrooves or micro undulations, the chamber wall being configured to have a thermal path free of liquid layers between an upper part of the condensing menisci where the vapour condenses and the latent heat of condensation is released and the upper ends of the evaporating menisci where the liquid evaporates and the latent heat of evaporation is absorbed. the arrangement comprising a liquid supplying system configured to supply the liquid to be evaporated without obstructions, in a direct and controlled manner, on the inner face of the chamber without undesired liquid overflows in the microgrooves or micro undulations in such a way that dry areas are reduced or eliminated; and wherein one section of the chamber wall of the chamber has a zigzag, crenellated or corrugated shape in the direction of the microgrooves or micro undulations, the chamber wall being configured to have a thermal path free of liquid layers between an upper part of the condensing menisci where the vapour condenses and the latent heat of condensation is released and the upper ends of the evaporating menisci where the liquid evaporates and the latent heat of evaporation is absorbed.
Blade adapted to be used in a streaming engine or compressor, wherein the blade contains a lower part , an upper part and an anchor element , wherein the anchor element is located inside of the blade , and wherein the anchor element connects the lower part and the upper part , characterized in that the blade consists of two parts and the anchor element, wherein the two parts have been manufactured using additive manufacturing. the blade consists of two parts and the anchor element, wherein the two parts have been manufactured using additive manufacturing.
An implantable device comprising a degradable outer housing comprising a degradable polymer, and an inner non-degradable portion comprising a non-degradable polymer, wherein the degradable outer housing is patterned, and the patterned portion comprises blood vessel geometries.
A binder for an injection molding composition, said binder consisting of, in percentage by weight and for a total of 100%: - 35% to 60% of a component (a), or "polymer base", consisting of a polymer or a mixture of polymers, each said polymer being non-amphiphilic and having a weight-average molar mass of greater than or equal to 5,000 g/mol, - 30% to 55% of a component (b), or "wax", consisting of a polymer or a mixture of polymers, each said polymer being non-amphiphilic and having a weight-average molar mass of less than or equal to 5,000 g/mol, and - less than 10% of an amphiphilic component (c), or "surfactant", and - less than 10% of other components (d), the polymer base comprising 2% to 15% of a styrene-ethylenebutylene-styrene copolymer or "SEBS", in percentage by weight based on the weight of the binder, the content by weight of styrene in the SEBS being greater than 15% in percentage by weight based on the weight of said SEBS, the weight-average molar mass of said SEBS being greater than 100,000 g/mol. - 35% to 60% of a component (a), or "polymer base", consisting of a polymer or a mixture of polymers, each said polymer being non-amphiphilic and having a weight-average molar mass of greater than or equal to 5,000 g/mol, - 30% to 55% of a component (b), or "wax", consisting of a polymer or a mixture of polymers, each said polymer being non-amphiphilic and having a weight-average molar mass of less than or equal to 5,000 g/mol, and - less than 10% of an amphiphilic component (c), or "surfactant", and - less than 10% of other components (d),
A dosing device for a gas engine having a gas mixer , in whose mixing chamber a combustible gas is dosed into an air mass flow , the dosing device comprising a highly dynamic pressure regulator (RP), comprising an actuator for pressure adjustment and to which a high-pressure reservoir (HD1) is connected via a high-pressure line, which supplies gas into an annular space surrounding the mixing chamber , and a controller ; and a pressure sensor measuring a gas pressure (P ist ); and a temperature sensor measuring a gas temperature (T gas ); and a lambda sensor measuring a lambda value (λ); and means for measuring or calculating the mass air flow (mL); wherein the measured or calculated signals are transmitted to the controller ; and wherein the controller controls the dosing of the highly dynamic pressure regulator (RP) at least as a function of the measured gas pressure (P ist ), the measured gas temperature (T gas ), the lambda value (λ) and the measured or calculated air mass flow (mL); characterised in that dosing bores lead from the annular space to the mixing chamber , whose bore diameters are configured such that a supercritical gas flow occurs in the dosing bores , and that the pressure sensor and the temperature sensor are arranged in the annular space , wherein the flow velocity in the supercritical flow depends only on the gas pressure and on the temperature in the annular space . a highly dynamic pressure regulator (RP), comprising an actuator for pressure adjustment and to which a high-pressure reservoir (HD1) is connected via a high-pressure line, which supplies gas into an annular space surrounding the mixing chamber , and a controller ; and a pressure sensor measuring a gas pressure (P ist ); and a temperature sensor measuring a gas temperature (T gas ); and a lambda sensor measuring a lambda value (λ); and means for measuring or calculating the mass air flow (mL); wherein the measured or calculated signals are transmitted to the controller ; and wherein the controller controls the dosing of the highly dynamic pressure regulator (RP) at least as a function of the measured gas pressure (P ist ), the measured gas temperature (T gas ), the lambda value (λ) and the measured or calculated air mass flow (mL); characterised in that dosing bores lead from the annular space to the mixing chamber , whose bore diameters are configured such that a supercritical gas flow occurs in the dosing bores , and that the pressure sensor and the temperature sensor are arranged in the annular space , wherein the flow velocity in the supercritical flow depends only on the gas pressure and on the temperature in the annular space .
A pharmaceutical composition comprising 1-(3- tert -butyl-1-p-tolyl-1H-pyrazol-5-yl)-3-(5-fluoro-2-(1-(2-hydroxyethyl)-1H-indazol-5-yloxy)benzyl)urea hydrochloride Form B, wherein said Form B is characterized by having at least one of: XRPD diffraction peaks (2θ degrees ± 0.3) at 12.3, 13.0, 15.9, 16.9 and 17.6; or XRPD diffraction peaks (2θ degrees ± 0.3) at 10.0, 12.3, 13.0, 15.9, 16.9, 17.6, 18.5, 23.4, 27.0 and 27.3; or XRPD diffraction peaks (2θ degrees ± 0.3) at 10.0, 12.3, 13.0, 15.9, 16.9, 17.6, 18.5, 20.4, 21.5, 21.9, 22.4, 23.4, 25.9, 27.0 and 27.3; or XRPD diffraction peaks (2θ degrees ± 0.3) at 10.0, 12.3, 13.0, 15.9, 16.9, 17.6, 18.5, 19.8, 20.4, 20.8, 21.5, 21.9, 22.4, 23.4, 23.9, 24.6, 25.2, 25.9, 27.0 and 27.3; or a DSC thermogram which comprises an endothermic event having a melt maxima temperature at 185 ± 5 °C; wherein the pharmaceutical composition comprises about 213 mg of 1-(3- tert- butyl-1-p-tolyl-1H-pyrazol-5-yl)-3-(5-fluoro-2-(1-(2-hydroxyethyl)-1H-indazol-5-yloxy)benzyl)urea hydrochloride Form B suspended in a carrier matrix, wherein said carrier matrix comprises Labrafac ® Lipophile WL 1349 and Vitamin E TPGS in a ratio selected from 10:90, 15:85, 30:70, and 33:67 and said Form B is present in a range from about 20-50% w/w relative to the weight of said composition, wherein said composition optionally further comprises an antioxidant, wherein the term "about" when relating to the proportion of 1-(3- tert -butyl-1-p-tolyl-1H-pyrazol-5-yl)-3-(5-fluoro-2-(1-(2-hydroxyethyl)-1H-indazol-5-yloxy)benzyl)urea hydrochloride Form B present in the composition refers to ± 2% by weight of the total composition. XRPD diffraction peaks (2θ degrees ± 0.3) at 12.3, 13.0, 15.9, 16.9 and 17.6; or XRPD diffraction peaks (2θ degrees ± 0.3) at 10.0, 12.3, 13.0, 15.9, 16.9, 17.6, 18.5, 23.4, 27.0 and 27.3; or XRPD diffraction peaks (2θ degrees ± 0.3) at 10.0, 12.3, 13.0, 15.9, 16.9, 17.6, 18.5, 20.4, 21.5, 21.9, 22.4, 23.4, 25.9, 27.0 and 27.3; or XRPD diffraction peaks (2θ degrees ± 0.3) at 10.0, 12.3, 13.0, 15.9, 16.9, 17.6, 18.5, 19.8, 20.4, 20.8, 21.5, 21.9, 22.4, 23.4, 23.9, 24.6, 25.2, 25.9, 27.0 and 27.3; or a DSC thermogram which comprises an endothermic event having a melt maxima temperature at 185 ± 5 °C; wherein the pharmaceutical composition comprises about 213 mg of 1-(3- tert- butyl-1-p-tolyl-1H-pyrazol-5-yl)-3-(5-fluoro-2-(1-(2-hydroxyethyl)-1H-indazol-5-yloxy)benzyl)urea hydrochloride Form B suspended in a carrier matrix, wherein said carrier matrix comprises Labrafac ® Lipophile WL 1349 and Vitamin E TPGS in a ratio selected from 10:90, 15:85, 30:70, and 33:67 and said Form B is present in a range from about 20-50% w/w relative to the weight of said composition, wherein said composition optionally further comprises an antioxidant, wherein the term "about" when relating to the proportion of 1-(3- tert -butyl-1-p-tolyl-1H-pyrazol-5-yl)-3-(5-fluoro-2-(1-(2-hydroxyethyl)-1H-indazol-5-yloxy)benzyl)urea hydrochloride Form B present in the composition refers to ± 2% by weight of the total composition.
A method for determining the amounts of A1-type beta-casein variants or A2-type beta-casein variants in a composition with greater than 80% accuracy, where the A1-type beta-casein variants are beta-casein variants having histidine at position 67 of the beta-casein amino acid sequence and the A2-type beta-casein variants are beta-casein variants having proline at position 67 of the beta-casein amino acid sequence, and where the composition is milk or a product prepared from milk, comprising the steps: (i) contacting the composition with chymotrypsin under conditions enabling digestion of beta-caseins in the composition by the chymotrypsin; (ii) obtaining an aqueous solution of beta-casein digestion peptides; (iii) determining the concentrations of: a) two or more beta-casein digestion peptides present in the solution, wherein each peptide comprises 8 to 20 amino acid residues and has histidine at a position corresponding to position 67 of the beta-casein amino acid sequence; and b) two or more beta-casein digestion peptides present in the solution, wherein each peptide comprises 8 to 20 amino acid residues and has proline at a position corresponding to position 67 of the beta-casein amino acid sequence; by analysing the mixture using liquid chromatography-mass spectrometry; and (iv) calculating the concentration of A1-type beta-casein variants in the composition or the concentration of A2-type beta-casein variants in the composition using the concentrations of the beta-casein digestion peptides determined in step (iii). (i) contacting the composition with chymotrypsin under conditions enabling digestion of beta-caseins in the composition by the chymotrypsin; (ii) obtaining an aqueous solution of beta-casein digestion peptides; (iii) determining the concentrations of: a) two or more beta-casein digestion peptides present in the solution, wherein each peptide comprises 8 to 20 amino acid residues and has histidine at a position corresponding to position 67 of the beta-casein amino acid sequence; and b) two or more beta-casein digestion peptides present in the solution, wherein each peptide comprises 8 to 20 amino acid residues and has proline at a position corresponding to position 67 of the beta-casein amino acid sequence; by analysing the mixture using liquid chromatography-mass spectrometry; and a) two or more beta-casein digestion peptides present in the solution, wherein each peptide comprises 8 to 20 amino acid residues and has histidine at a position corresponding to position 67 of the beta-casein amino acid sequence; and b) two or more beta-casein digestion peptides present in the solution, wherein each peptide comprises 8 to 20 amino acid residues and has proline at a position corresponding to position 67 of the beta-casein amino acid sequence; (iv) calculating the concentration of A1-type beta-casein variants in the composition or the concentration of A2-type beta-casein variants in the composition using the concentrations of the beta-casein digestion peptides determined in step (iii).